The ease of administration makes this useful for large-scale field administration, for use with pediatric or elderly patients as well as patients in Third-World populations.

About

Summary This invention is a method of vaccinating against human papillomavirus (HPV) by using papillomavirus ?virus-like particles? transcutaneously to induce an immune response to the virus. Papiloma viruses constitute a group of DNA viruses that induce both lytic infections and either benign or malignant tumors. Papiloma viruses infect cutaneous, genital, oral, and respiratory epithelia in a tissue-specific manner. Infection with HPV has been associated closely with plantar warts, condylomata acuminata (anogenital warts), and premalignant and malignant lesions of the cervical squamous epithelium.

Register for free for full unlimited access to all innovation profiles on LEO

  • Discover articles from some of the world’s brightest minds, or share your thoughts and add one yourself
  • Connect with like-minded individuals and forge valuable relationships and collaboration partners
  • Innovate together, promote your expertise, or showcase your innovations